Hepatitis C

Quote
Anonymous said:
Told you dummy that the Genotype 1 data was coming. and it looks GOOOOOOOD. you had better believe this is being fast tracked. 100% Genotype 1 at 4 WEEKS?? Damn! No Peg interferon as I mentioned before. This is game changing data and even more to follow soon. Both Gild and BMS have solid, well seasoned Hep reps so all of those offers knocking on your door might not be as plentiful as you think. stay tuned...
Click to expand...

Actually, the BMS reps are idiots as is the company. If they were to launch a HCV drug, it would take 6 months for the providers to learn about it. They'll frig up a launch with the worst of them. As for Gilead, they're best relations are with Asian MDs.
 












Anonymous said:
Crack head here!
1 and 2) Sales force sizing is constantly re-evaluated, for ALL sales forces. I have already stated that the sheer dominance of Pegasys could cause cuts, as obviously the drug has minimal competition, and pretty much sells itself at this point; the fight against PegIntron is over! However, speculating on the scope and timing of any change is just that, speculation. "trimming" the sales force is not the same as the imminent doom and gloom predicted by the Original poster. There simply is no indication of a pending reduction, so why speculate, and spout numbers as though they were fact?

3) Biosimilars? Why are we even discussing this, the Pegasys patent does not even expire until 2015! Thats 3-4 years before a Biosimilar can hit the market, and that assumes no patent extensions, and that there is interest in pursuing such a drug. In the drug industry, four years is a lifetime.

4) Profitabilty- ALL companies want maximum profitability, not just "BASEL"; and that means all! All considerations of sales force sizing are considered against the backdrop of sales thus profitabilty. With minimal managed care impact (98% parity vs peg intron), pegasys is a highly profitable drug. Drug reps are not really sales people, they are resources that are deployed as tactics; just like TV commercials, Radio ads, bill boards, print ads, teledetailing, etc. Reps are expensive, but there is a reason that they are used, that is "THEY WORK"; this is a fact! It would make little sense to have dramatic cuts in a sales force, when it is clear that they have caused and have sustained such dramatic success. "Tweaking" yes? doom and gloom scenario espoused by the OP, no!


In conclusion, there is no need for alarm, and there is no pending doom and gloom, at least that you or I know of. These are the facts, Pegasys is being studied with EVERY SINGLE DAA drug in the HCV pipeline; Pegasys does not lose its patent for 3-4 years, and there is no know biosimilar in the pipeline; there is no ALL ORAL therapy. in phase 2 or phase 3 for genotype 1 HCV, hence, any ALL ORAL regimen is years away from being a reality; Roche HCV is the most experience and most successful sales force in the burgeoning HCV market. Our reps will be highly sought after, as these new companies come online, as there simply are not many reps with HCV experince, knowledge, and relationships. The fact of the matter is short term (3-4), even if Pegasys is our only product, most of us have nothing at all to worry about; and long term we will have plenty of opportunities. Trust me when I tell you that management worries much more about mass defections, than layoffs of 10 or 15 reps. And yes, like ALL reps, and others, your resume should always be polished, but there is no pending doo and gloom.
Click to expand...

The amusing thing is that none of the top management at any of these companies have partnered with a testing company to fill the funnel while the time is ripe.
 












Top Bottom
Back
Quote